International Journal of Radiation Oncology*Biology*Physics Study Finds that Resonant Medical's Clarity Breast System Provides Enhanced Image Information for Planning Partial Breast Irradiation Treatment
MONTREAL, March 4 /PRNewswire/ -- Researchers report in the February 1st issue of the International Journal of Radiation Oncology*Biology*Physics that the use of 3D ultrasound with the Clarity(TM) Breast System provided enhanced image information to enable radiation oncologists to better define the treatment region when delivering partial breast irradiation treatment (PBI) for breast cancer. The Clarity Breast System marks the first application of 3D ultrasound technology to Image-Guided Radiation Therapy (IGRT) and was developed by Resonant Medical, an innovator of 3D ultrasound image-guided adaptive radiotherapy products.
The study, "3D Ultrasound Can Contribute to Planning CT to Define the Target for Partial Breast Radiotherapy," conducted at the Radiation Therapy Program, British Columbia Cancer Agency, Vancouver Island Centre and the
"Precision in planning and the increased certainty that radiation is being delivered to the exact area where it is needed have never been more critical, with the percentage of patients opting for breast conservation therapy and PBI on the rise," said Pauline Truong, MD, CM, a researcher on the study. "Following this study, however, it is clear that the benefits of this technology could be applicable to not only PBI patients, but those undergoing whole breast radiation and electron boost therapy - potentially helping an even larger population of women with breast cancer."
The Clarity Breast System marks the first application of 3D ultrasound technology to Image-Guided Radiation Therapy (IGRT) in breast cancer. The Clarity system was cleared by the U.S. Food and Drug Administration in 2004 for guidance in the treatment of prostate and breast cancers.
In addition to its application with treatment planning, the Clarity System is also used to image the lumpectomy cavity daily with each radiation treatment, to get an actual visual image and location of the tumor cavity on a regular basis. While the breast cancer radiation oncology community is aware that the location of the lumpectomy cavity target can change throughout the course of treatment, this issue is still largely unaccounted for in current treatment protocols. Clinical consequences can include delivery of radiation to healthy tissue, application of radiation too close to the chest wall or skin and, in some cases, under-treatment of certain areas. Clarity provides the first method of daily lumpectomy cavity monitoring that is based on visualization of the actual anatomy--rather than an estimation of the location of the cavity. This precision in planning and treatment could enable physicians to reduce the field of radiation they need to deliver, which is always preferable if clinically justified.
Several studies detailing the benefits of the use of Clarity during breast cancer treatment have also been presented in recent months. For example:
"The Clarity System has been used in the treatment of thousands of prostate cancer patients, and we are encouraged by the results and feedback we have seen and heard from radiation oncologists regarding its application with breast cancer," said Tony Falco, PhD, FCCP, Founder and Chief Executive Officer of Resonant Medical. "This mounting clinical evidence acknowledges the value of the Clarity system for the effective planning and treatment of breast cancer."
About Resonant Medical
Resonant Medical (Montreal, Canada) develops, manufactures and commercializes 3D ultrasound image-guided adaptive radiotherapy products. Originally developed at
Contacts: Wendy Ryan/Jasmine Fielding Schwartz Communications (781) 684-0770 Resonant@schwartz-pr.com
|SOURCE Resonant Medical|
Copyright©2009 PR Newswire.
All rights reserved